Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss

[Display omitted] •Probucol suppresses RANKL-induced osteoclast formation and function.•Probucol inhibits RANKL-induced oxidative stress, MAPKs and NF-κB signaling pathways.•Probucol inhibits osteoclastogenesis by regulating Nrf2.•Probucol can alleviate bone loss caused by estrogen deficiency. Osteo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2023-03, Vol.116, p.109820-109820, Article 109820
Hauptverfasser: Guo, Jiachao, Ren, Ranyue, Guo, Zhou, Sun, Kai, He, Jinpeng, Shao, Jingfan, Wang, Xiaolin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Probucol suppresses RANKL-induced osteoclast formation and function.•Probucol inhibits RANKL-induced oxidative stress, MAPKs and NF-κB signaling pathways.•Probucol inhibits osteoclastogenesis by regulating Nrf2.•Probucol can alleviate bone loss caused by estrogen deficiency. Osteoporosis is a systemic and endocrine bone disorder distinguished by declined bone mineral density, compromised bone strength, and destruction of trabecular structure. The abnormally excessive osteoclastogenesis and bone erosion play imperative roles in the progression of osteoporosis. However, treatment of osteoporosis is far from satisfactory due to poor adherence to existing medications and adverse reactions, there is an urgent to develop novel therapies for osteoporosis. Probucol, a synthetic compound with two characteristic phenolic rings, owns anti-inflammatory and antioxidant properties. Accumulating evidence have indicated that intracellular reactive oxygen species (ROS) is closely related to osteoclastogenesis. Hence, we investigated the potential effects of probucol on osteoclastogenesis in vivo and in vitro. In this study, TRAP staining and bone slice resorption assay showed that probucol suppressed RANKL-induced osteoclast formation and function. The mRNA and protein levels of osteoclastogenesis marker genes were reduced by probucol in a concentration-dependent manner. Besides, probucol suppressed osteoclast differentiation by inhibiting ROS production, MAPKs and NF-κB signaling pathways, while Nrf2 silencing reversed the inhibitory effect of probucol on osteoclast formation and function. Consistent with the above findings, in vivo experiments demonstrated that probucol visibly alleviated bone loss caused by estrogen deficiency. In brief, these results showed the potential of anti-oxidant compound probucol in the treatment of osteoporosis, highlighting Nrf2 as a promising target in osteoclast‐related disease.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2023.109820